(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/139090 A1

(51) International Patent Classification:
A61K 39/00 (2006.01)

(21) International Application Number:
PCT/EP2023/051073

(22) International Filing Date:
18 January 2023 (18.01.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2200592.0 18 January 2022 (18.01.2022) GB

(71) Applicant: **ARGENX BV** [BE/BE]; Industriepark Zwijnaarde 7, 9052 Gent (BE).

(72) Inventors: **HEUZÉ-VOURC'H, Nathalie**; 179 rue Giraudeau, 37000 Tours (FR). **VAN DER WONING, Paul Sebastian**; c/o ARGENX BV, Industriepark Zwijnaarde 7, 9052 Gent (BE). **PERCIER, Jean-Michel**; c/o ARGENX BV, Industriepark Zwijnaarde 7, 9052 Gent (BE).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London Greater London EC4Y 8AP (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

WO 2023/139090 A1

(54) Title: NEBULIZATION OF FAB FRAGMENTS

Figure 1 continued

B.



(57) Abstract: The present invention relates to methods of treating a disease or condition associated with the presence or formation of galectin-10 crystals, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a Fab fragment that binds to galectin-10, wherein the composition is administered as an aerosol. Also included within the invention are pharmaceutical compositions comprising a Fab fragment that binds to galectin-10, and nebulizers comprising said pharmaceutical compositions. The pharmaceutical compositions may be useful for treating a disease or condition associated with the presence or formation of galectin-10 crystals, such as asthma or cystic fibrosis.

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*